ARTICLE | Management Tracks
Thomas Butler steps down as Biomea CEO
Plus: Shane Olwill named chief development officer of Asgard, and updates from Tevogen and Verrica
March 27, 2025 1:15 AM UTC
Thomas Butler is stepping down as CEO of Biomea Fusion Inc. (NASDAQ:BMEA) after over six years. Mick Hitchcock, a director for the past four years and a 27-year veteran of Gilead Sciences Inc. (NASDAQ:GILD), becomes interim CEO. Biomea’s lead small molecule, icovamenib, is in Phase II trials for Type I and II diabetes.
Shane Olwill became chief development officer of Asgard Therapeutics AB, which is developing in vivo cell reprogramming gene therapies for cancer. Olwill was SVP, CDO at Pieris Pharmaceuticals Inc., which merged with Palvella Therapeutics Inc. (NASDAQ:PVLA) ...